Pipeline

Antibody

  • EU101 Fully humanized anti-human 4-1BB monoclonal antibody. Agonistic effect of EU101 promotes cytotoxic T lymphocyte response and it leads to eradication of cancer.
    Discovery Non-clinical Phase I Phase II
  • EU103 Fully humanized therapeutic monoclonal antibody. This could convert type II macrophage to Type I. Anti-tumor efficacy of the antibody can be achieved by modulating tumor microenvironment.
    Discovery Non-clinical Phase I Phase II
  • EU501(HER2 x 4-1BB) 4-1BB mAb-based, tumor antigen targeting bispecific antibodies.
    Discovery Non-clinical Phase I Phase II